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Abstract
Study objective—Hysterectomy for presumed leiomyomata is one of the most common surgical 
procedures performed in non-pregnant women in the United States. Laparoscopic hysterectomy 
(LH) with morcellation is an appealing alternative to abdominal hysterectomy (AH), but may 
result in dissemination of malignant cells and worse outcomes in the setting of an occult 
leiomyosarcoma. We sought to evaluate the cost-effectiveness of LH versus AH.
Study Design—Decision-analytic model of 100,000 women in the United States assessing the 
incremental cost-effectiveness ratio (ICER) in $/QALY gained.
Design Classification—Canadian Task Force Classification III
Setting—U.S. hospitals.
Patients—Adult premenopausal women undergoing LH or AH for presumed benign 
leiomyomata.
Interventions—We developed a decision-analytic model from a provider perspective across 
five-years, comparing the cost-effectiveness of LH to AH in terms of dollar (2014 USD) per 
quality adjusted life-year (QALY) gained. The model included average total direct medical costs 
and utilities associated with the procedures, complications, and clinical outcomes. Baseline 
estimates and ranges for cost and probability data were drawn from the existing literature.
Measurements and Main Results—Estimated overall deaths were lower in LH vs AH (98 vs 
103). Death due to leiomyosarcoma was more common in LH vs AH (86 vs 71). Base-case 
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assumptions estimated that average per person costs were lower in LH vs AH - a savings of 
$2,193 ($24,181 vs $26,374). Over five years, women in LH group experienced 4.99 QALY, 
versus women in AH group with 4.91 QALY (incremental gain of 0.085 QALYs). LH dominated 
AH in base-case estimates - LH being both less expensive and yielding greater QALY gains. The 
ICER was sensitive to operative costs for LH and AH. Varying operative costs of AH yielded an 
ICER of $87,651/QALY gained (minimum) to AH being dominated (maximum). Probabilistic 
sensitivity analyses, in which all input parameters and costs were varied simultaneously, 
demonstrated a relatively robust model. The AH approach was dominated 68.9% of the time. 
17.4% of simulations fell above the willingness-to-pay threshold of $50,000/QALY gained.
Conclusions—When considering total direct hospital costs, complications, and morbidity, LH 
was less costly and yielded more QALYs gained versus AH. Driven by the rarity of occult 
leiomyosarcoma and the reduced incidence of intra- and postoperative complications, LH with 
morcellation may be a more cost-effective and less invasive alternative to AH and should remain 
an option for women needing hysterectomy for leiomyomata.
Introduction
Hysterectomy for presumed leiomyomata (fibroids) is one of the most common surgical 
procedures performed in non-pregnant women in the United States, with over 200,000 
performed annually 1. Surgeons increasingly employ less invasive laparoscopic techniques 
for both supracervical and total hysterectomies, shortening hospital stay and recuperation 
time 2,3. In laparoscopic procedures, when the uterus is too large to be removed intact 
vaginally, the specimen must be cut into smaller pieces for removal via the smaller 
abdominal incisions. This dissection of solid tissue, so-called morcellation, may result in 
unintentional intra-abdominal spread of tissue fragments 4,5. In the setting of previously 
undiagnosed leiomyosarcoma, morecellation may result in dissemination of malignant cells. 
The consequences of morcellation in the context of occult malignancy has sparked a heated 
debate regarding the risks associated with laparoscopic hysterectomy and morcellation 6.
The prevalence of occult leiomyosarcoma among women undergoing hysterectomy for 
presumed fibroids is not precisely known, but available reports indicate it is extremely 
rare 5,7–9, and difficult to distinguish from benign disease preoperatively 10. For women with 
large fibroids, the benefits of a laparoscopic approach to hysterectomy—lower overall 
mortality, fewer intraand postoperative complications, improved quality of life, and lower 
cost—must be weighed against the uncommon risk of morcellation of an occult 
malignancy 3,10,11. With governing bodies and hospital systems struggling with how to best 
address this clinical problem, additional insights into both the health and economic 
consequences of laparoscopic and abdominal hysterectomies are critically needed.
In this study, we evaluated the cost-effectiveness of laparoscopic hysterectomy with 
morcellation for removal of presumed fibroids as compared to abdominal hysterectomy. We 
estimated the total per person direct hospital costs associated with both procedures and the 
anticipated associated intraoperative and postoperative complications from existing 
literature. Our primary outcome was the incremental cost-effectiveness per quality adjusted 
life year (QALY) gained.
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Methods
We developed a decision-tree model (Figure 1), constructed using Excel™ 2010 (Microsoft 
Corp, Redmond, WA, USA) and TreePlan™ (TreePlan Software, San Francisco, California) 
to simulate costs, outcomes, and incremental cost-effectiveness ratios (ICERs) comparing 
laparoscopic hysterectomy with morcellation (LH) to abdominal hysterectomy (AH). AH is 
considered the base case scenario, with LH evaluated as the alternative. An ICER in which 
the alternative (LH) is less expensive and more effective (more QALYs gained) compared to 
AH would be interpreted as “dominant” 12. Costs and outcomes were evaluated across a 5-
year time horizon. This study was considered exempt from review by the Institutional 
Review Board at the University of North Carolina at Chapel Hill, as it involved synthesis 
and analysis of existing published data.
Mortality, complications, and quality of life
Assumptions regarding anticipated clinical events and associated QALYs are presented 
elsewhere 13. Briefly, we simulated a hypothetical cohort of 100,000 adult premenopausal 
(i.e., still menstruating) women undergoing either LH or AH for presumed benign 
leiomyomata. This hypothetical cohort is limited to women with a uterus large enough that it 
would either require laparotomy or laparoscopy with morcellation. Women who could have 
intact removal through the vagina are not included as they are not the focus of this 
investigation. We examined frequency of transfusion, wound infection, venous 
thromboembolism (VTE), incisional hernia, vaginal cuff dehiscence, overall mortality, and 
complications associated with occult leiomyosarcoma. All women were at risk for surgical 
complications associated with hysterectomy, represented as unique and independent health 
states in the model. The base-case estimates and ranges for mortality, probabilities of 
complications, and utilities were determined by literature review (Table 1). We derived 
leiomyoscarcama estimates, weighting high-quality more recent studies with larger sample 
size that used pathologic diagnostic criteria. The base case estimate for leiomoysarcoma risk 
(6/5084; 0.0012) was derived using mean estimates of leiomoysarcoma rates from the four 
highest-quality studies – 0.00089, 0.0007 7, 0.0009 5, 0.00238. The range that was used in 
one-way and probabilistic sensitivity analyses use the lowest and highest reported rate of 
occult disease among studies with a sample size greater than 1000, ranging from 0.00077 to 
0.0049 14, a range inclusive of the most recent FDA estimate6.
In terms of sarcoma-related mortality, the estimates from death from sarcoma were taken 
from SEER based 5-year mortality reporting on LMS outcomes in the United States and 
varied depending on if a woman underwent TAH or TLH based on the presumed up-staging 
of disease due to dissemination during morcellation. We assumed that women with 
metastatic disease would be identified preoperatively and would not be included in this 
hypothetical cohort. Survival of women with distant metastases is likely driven by the 
metastatic disease, so morcellation would not change their stage nor impact overall survival, 
meaning the post-operative prognosis would not vary for women with preoperative stage IV 
disease. We assumed that occult LMS in a woman undergoing TAH is represented by 
International Federation of Gynecology and Obstetrics stage I or stage II diagnosis (confined 
to the pelvis) and that morcellation (TLH), with its theoretical dissemination of cancer cells, 
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would, at worst lend the same poor prognosis as spontaneous cancer metastasis, a stage III 
diagnosis (extra-pelvic disease). Therefore, the probability of death following sarcoma after 
TAH was set as 5 year death rate of stage I–II (weighted average) disease (0.59), and the 
probability of death following sarcoma after TLH was set at 5 year death rate of stage III 
disease: 0.7215. Thus all women with occult LMS who underwent TLH were given a worse 
prognosis than those undergoing TAH. The survival was not calculated annually, as the best 
population-estimates available are traditional 5-year rates. We also examined more recent 
observational studies of LMS cohorts, including 315 patients treated from 1982 – 
2010 16–18. These were similar to the population-based SEER estimates and therefore the 
estimates were not changed. We assumed that patients with LMS received adjuvant 
chemotherapy regimens (gemcitabine and carboplatin).
Health utility estimates were derived for each health state, accounting for the average 
duration that an individual would remain in that state.
Cost inputs
We used a provider perspective and included direct medical costs associated with surgical 
procedures, intraoperative or postoperative complications, and cancer-related care, as 
reported in the literature (Table 1). For women with leiomyosarcoma, we included costs 
associated with cancer-directed treatment and/or palliative care, as reported in the literature. 
The costs that we report are direct medical costs or reimbursed medical costs in US dollars 
for care delivered, as opposed to prices charged. We chose this approach to costing because 
prices charged vary substantially across hospitals and settings, may not be generalizable to 
all patients, and may not be indicative of actual resources required to deliver services. 
Because we employed the provider perspective, indirect, non-medical costs (such as patient 
transportation costs) were not relevant and were not included in our analysis.
All costs (in 2014 USD) were derived from published literature. Costs collected prior to 
2014 were inflated using historical consumer price index data for urban consumers, medical 
care expenditure category 19. Procedural costs for abdominal and laparoscopic 
hysterectomies were derived from retrospective cohort analyses 20,21, and a randomized 
clinical trial 22. In this case, surgical procedural costs were derived from micro-costing 
approaches and included operative expenses, supplies, equipment and instruments, and 
physician and staff costs. Operative expenses were derived using accounting ledgers, where 
costs were associated with operative time (staffing costs) using an institutional time-based 
linear algorithm. Both of the retrospective trials were conducted in the US. By contrast, the 
randomized clinical trial was conducted in Sweden, and in that setting, the procedural costs, 
including equipment and OR-related staffing expenses, were considerably less than those 
reported by the US-based trials. Accordingly, we used the Swedish estimates as the low-end 
of the cost range for procedure-associated costs.
Costs for surgery-related complications were derived from several sources. Transfusion 
costs included total direct hospital costs for laboratory services, staff labor, and 
materials23,24. Total direct hospital costs for management of surgical site infections were 
derived from patient-level micro-costing approach based on supplies and staff-time 25, and 
ICD-9 diagnosis codes for postoperative surgical site infections in gynecologic surgical 
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procedures 26. Total direct hospital costs for hernia repair were based on a retrospective 
analysis of patients who underwent repair for a ventral hernia27. Estimates included average 
total direct hospital cost associated with length of stay, operating room time, time in 
intensive care units, resuscitation, and any costs associated with related readmissions. We 
were unable to identify costs associated with repair of vaginal cuff dehiscence and therefore 
assumed that the costs would be similar to those of hernia repair, based on the invasiveness 
of treatment and spectrum of clinical complications.
Published hospital cost data were not available for VTE or leiomyosarcoma therapy and 
associated end-of-life care. The best available studies rely on reimbursement, which is 
related to hospital costs, but not identical. However, we conducted sensitivity analyses to 
assess the impact of these cost inputs on overall model-projected cost and cost-effectiveness 
estimates. Costs for VTE were based on a retrospective cohort analysis of reimbursed costs 
from administrative insurance claims databases in large US private health care plans 28, and 
a retrospective analysis from a national database of hospital claims evaluating provider 
payments and reimbursements for cost of hospitalization 29. Chemotherapy costs were 
derived from Medicare reimbursements processed from ICD-9 diagnosis codes and 
procedural codes (CPT and HCPCS codes) for the treatment of leiomyosarcoma assuming 
six one-month cycles of concurrent docetaxel and gemcitabine, and included drug costs and 
costs associated with drug-related toxicities (neuropathy and neutropenia), weighted 
probabilistically based on the likelihood that such toxicities occur30. In addition to drug and 
toxicity management costs, cancer care costs included physician visits, all infusion and 
related /treatment charges, and the costs of standard pretreatment medications. We assumed 
that patients who did not respond to the first six-month cycle of chemotherapy would incur 
costs associated with a second six-month cycle and eventually end-of-life care. Costs 
associated with end-of-life care were based on reimbursements from Medicaid 
administrative claims data among beneficiaries who died after a cancer diagnosis compared 
to a matched cohort of beneficiaries who died of other causes, using reimbursed costs 
specific to gynecologic cancer patients31.
Base case analysis
We used base case cost and utility estimates to compare differences between AH and LH. 
We subtracted the base case AH costs from LH costs and base case AH utilities from LH 
utilities, and then divided the cost difference (incremental cost) by the difference in utilities 
(incremental effectiveness) to yield the base case ICER.
Sensitivity analyses
We performed one-way, deterministic sensitivity analyses for parameters identified as major 
drivers of the ICER outcome, holding all else constant. We conducted a probabilistic 
sensitivity analysis (PSA) using Monte Carlo simulations (1000 trials) for the ICER 
outcome (Crystal Ball version 11.1.2.3 [Oracle, Redwood Shores, CA, USA]). In this 
process, probability distributions are assigned based upon expected ranges for all input 
parameters (probabilities, utilities, and costs) and then values for each parameter are drawn 
randomly from within these distributions to generate our outcome of interest 3233. Table 1 
details the distributions that we used in the PSA. For example, for an input parameter with a 
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triangular distribution, with each simulation, the value of that point estimate may be 
anywhere within the pre-defined parameter range, with values closer to the base case being 
more likely to be drawn than those towards the tail (minimum and maximum). In this way, 
we vary the inputs across the parameter range in 1000 distinct scenarios, and in doing so, 
examine the uncertainty around all ranges. The probabilistic sensitivity analysis allows for 
natural stochasticity due to chance as well as uncertainty in the value of input parameters 
that may arise across diverse studies and samples.
The range of probability parameters are detailed elsewhere13. In brief, all probabilities were 
selected using literature review of primary data, with preference to higher quality and more 
recent studies that appropriately reflect advances in the field. Table 1 details the base case 
parameter values employed as well as relevant ranges selected for sensitivity analyses. 
Probabilities and utility estimates assumed triangular distributions. Given limited reports on 
utilities for the health states in our model, all utilities were varied by 20% above and below 
the base-case estimate. We assumed a gamma distribution for costs considering the base-
case estimate evaluated over the literature-informed range12. Gamma distributions were 
selected for utilities in that this distribution is constrained to be positive and fully 
continuous.
Because total direct hospital cost data were not available for VTE or leiomyosarcoma-
related costs (chemotherapy and/or end-of-life care), we conducted extensive a priori 
individual one-way sensitivity analyses with these cost inputs, varying base case estimates 
by +/− 40%.
In an alternative scenario, we modeled the effect of patients with progressive 
leiomyosarcoma dying in year two of the model, rather than surviving to year five. In this 
analysis, patients with leiomyosarcoma who did not respond to the initial six-month course 
of chemotherapy no longer contributed QALYs to the model beyond year two. These 
women still received a second course of chemo and end-of-life care. This represents a more 
conservative scenario that would tend to favor AH, as more women in the LH arm may have 
progressive leiomyosarcoma.
Results
In our model of 100,000 premenopausal women undergoing hysterectomy for presumed 
leiomyomata, we estimated that overall deaths were lower in LH vs AH (98 vs 103). 
However, death due to leiomyosarcoma was more common in LH vs AH (86 vs 71). Using 
base-case assumptions, we estimated average per person costs as lower in LH compared to 
AH, resulting in a savings of $2,193 for LH patients ($24,181 vs $26,374) (Table 2). Over 
five years, women in the LH group experienced 4.99 QALY, compared to women in the AH 
group with 4.91 QALY, for an incremental gain of 0.085 QALYs. As such, LH dominated 
AH in base-case estimates, with LH being both less expensive and yielding greater QALY 
gains.
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Sensitivity analyses
In one-way sensitivity analyses, we estimated the potential range of ICERs across the 
probable range of input parameters (Table 3). The ICER was especially sensitive to 
operative costs and the estimated quality-of-life decrement associated with AH. Using the 
minimum ($7,268) and maximum ($35,584) estimate for LH operative costs, the ICER 
comparing LH to AH varied from AH being dominated (negative ICER) to LH resulting in 
$120,259/QALY gained, which is above the commonly accepted $50,000/QALY gained 
threshold, indicating that we would not adopt LH over AH. Univariate analyses that varied 
operative costs of AH between minimum ($12,281) and maximum ($32,648) yielded an 
ICER of $87,651/QALY gained when evaluated at the minimum AH operative cost, to AH 
being dominated at the maximum AH operative cost. These analyses suggest that the ICER 
is very sensitive to the operating costs of LH and AH. Varying the utility estimate for the 
health-related quality of life associated with undergoing AH (0.72, 1.0) continued to 
demonstrate that LH dominated AH across the predefined range of utilities for this 
parameter.
Because we had to rely on reimbursement instead of total direct hospital costs for VTE, 
leiomyosarcoma treatment, and end-of-life care, we conducted one-way sensitivity analyses 
for the inputs, extending the range +/−40% of base case. Results suggest that the ICER 
outcome was not sensitive to these costs; AH remained dominated across the wide range of 
costs for each parameter.
Probabilistic sensitivity analyses, in which all input parameters and costs were varied 
simultaneously, demonstrates a relatively robust model. Each draw results in a new 
incremental cost and incremental effectiveness of LH compared with AH. Resulting point 
estimates (Figure 2) represent the ICERs of the 1000 draws executed through Montel Carlo 
simulations. The AH approach is dominated (i.e., the strategy is both less effective and more 
costly compared with LH) 68.9% of the time. The remaining 31.1% of simulations lie in the 
“tradeoff” zone in which LH is both more effective and more costly than AH; 17.4% of 
simulations fell above the willingness-to-pay threshold of $50,000/QALY gained.
The base-case ICERs continued to demonstrate LH dominating AH when women with 
leiomyosarcoma died in year two of the model, rather than living at reduced quality-of-life 
for years three to five.
Discussion
In our base case analysis, we found that LH dominated AH. When considering the total 
direct medical costs associated with each procedure, resulting complications, and morbidity, 
LH was less costly and yielded more QALYs gained compared to AH. Despite the potential 
risks associated with dissemination of malignant tissue during the morcellation process, the 
rarity of preoperatively undiagnosed leiomyosarcoma and the reduced intra- and 
postoperative complication rates suggest that on a population level, across the probable 
range of inputs, LH is likely a more cost-effective alternative compared to AH. Probabilistic 
sensitivity analyses demonstrate robust model performance with simultaneous and random 
draws from the probable range of complication probabilities, estimated utilities, and 
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associated costs. In simulations, the majority of ICER outcomes were negative; that is, 
compared to AH, LH was less costly and marginally more effective in terms of QALYs 
gained.
The incremental QALYs gained were minimal comparing LH to AH. This suggests that 
despite the less-invasive laparoscopic approach, LH is associated with only moderate 
benefits in terms of QALYs once the risk of leiomyosarcoma is considered. This limited 
variability in QALYs is likely driven by the fact that most women proceed through the 
model without experiencing any complication. Women in the LH group who do not 
experience complications are modeled as having a health-related quality-of-life of 1 
(maximum utility) throughout the five-year model time horizon. Conversely, women in the 
AH group who do not sustain complications, the majority of women, experience decreased 
health-related quality-of-life associated with recovery from an open surgical procedure (0.9) 
for the six-month period immediately following surgery 34. However, even in a sensitivity 
analysis adopting the more conservative assumption that women undergoing AH do not 
have any health-related quality-of-life decrement postoperatively, the ICER for LH 
continued to dominate AH.
Importantly, perceived utility of a given health state, and thus the estimated QALY resulting 
from occupying that health state, may vary according to age, income status, and other 
socioeconomic factors. Granular detail specifying this level variation within this particular 
patient population is not currently available, and therefore, aggregate health utility estimates 
may mask some of the demographic and socioeconomic variation in these values. We 
attempted to mitigate this limitation by varying all utility estimates by 20% above and below 
the base-case estimate. However, future studies should seek to explore sub-population 
specific variation in health related quality of life reporting.
Women undergoing AH were more likely to experience an immediate (i.e., transfusion) 
and/or longer-term (i.e., hernia) complication. Vaginal cuff dehiscence was the only 
complication that was more common among women undergoing LH35–37, perhaps 
attributable to electrosurgical rather than sharp colpotomy or inadequate tissue inclusion 
during cuff closure38,39. The consequences of vaginal cuff dehiscence are highly variable, 
depending on the degree of evisceration. We did not explicitly model the variability of 
dehiscence complications, but rather focus on its average morbidity and costs.
Total direct hospital cost data were drawn primarily from US-based studies. Operative costs 
for AH and LH, the major driver of ICER outcomes, were from studies conducted in the last 
five years. More recent cost estimates for some complications, including transfusion, 
surgical site infection, and VTE, were not available. However, these costs did nto 
dramatically influence ICER estimates in sensitivity analyses. There was variability in the 
method of ascertaining costs across studies, resulting in uncertainty regarding the estimated 
costs. Ideally, all costs, including those associated with the procedure and any follow-up 
interventions due to procedural complications, would be assessed using micro-costing 
techniques in which a cohort of patients was followed prospectively and all costs obtained 
using hospital data. However, this highly intensive approach was not feasible and was 
beyond the scope of this study. Nevertheless, in sensitivity analyses, we were able to address 
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the uncertainty associated with costs and found that despite varying reimbursement-derived 
costs by a generous +/−40% range and other costs according to the best available data, AH 
remained dominated by LH in the majority of simulations, demonstrating that these costs 
were not a major driver of our ICER outcome. Indeed, in extensive sensitivity analyses 
pursued in this study, the only costs that had a substantial influence on ICER outcomes were 
the procedural costs of LH and AH, which came from robust cohort and randomized trials 
using total direct hospital cost estimates. Assessment and inclusion of indirect costs were 
beyond the scope of this study due to our provider perspective. However, inclusion of 
indirect costs, such as time away from work (lost wages, lost productivity), would likely 
favor LH over AH given differences in expected recovery time.
Our original decision analysis and this cost-effectiveness analysis focused on laparoscopic 
hysterectomy. Data are mixed regarding cost robotically-assisted hysterectomy40–42. If the 
robotic platform indeed raises the cost of the operation, it would temper the benefit observed 
for laparoscopy in this cost analysis. That said, while clear advantages for laparoscopy over 
laparotomy in patient outcomes, there are no demonstrable advantages for robotic 
laparoscopy over conventional laparoscopy. In the context of this model, morcellation 
captures all procedures involving the cutting of uterine tissue to facilitate laparoscopic 
removal. Data are lacking regarding safety differences between various morcellation 
techniques, preventing stratification by type of morcellation. The few studies that suggest 
survival differences in patients with leiomyosarcoma comparing surgery with and without 
morcellation include a heterogeneous set of extraction modalities11,43.
There are limited and highly variable data regarding the incidence of occult leiomyosarcoma 
in the setting of hysterectomy for presumed leiomyomata5,7–9,14,44–48. We modeled the 
increased risk of disease progression and mortality in the setting of morcellation with LH 
compared to AH. Even at the highest incidence estimate, the ICER for LH continued to 
dominate AH. Ongoing endeavors to develop improved containment tools during uterine 
extraction or improved diagnostics to distinguish between benign and malignant myomata 
could markedly reduce risk associated with tissue dissemination during morcellation. We 
chose to focus specifically on leiomyosarcoma because this is the malignancy which mimics 
large leiomyomata and our knowledge of the effect of morcellation on leiomyosarcoma 
(limited as it is) is better understood than the effect on other malignancies 49. We did not 
model endometrial or cervical cancers explicitly, as these are distinct entities from 
leiomyosarcoma in that we have significantly better preoperative diagnostic testing for 
endometrial and cervical cancer. Furthermore, uteri with occult endometrial or cervical 
cancer can presumably be much more frequently be delivered intact through the vagina, 
avoiding morcellation altogether, and thus are less relevant to the model as designed here.
This cost-effectiveness analysis, and the clinical outcomes analysis that preceded it 13, are 
meant to inform policymakers, clinicians, and other decision makers in what has emerged as 
the most debated issue in gynecologic surgery. Like all medical procedures, a woman's 
decision to undergo laparoscopic or abdominal hysterectomy should include a thorough 
discussion of risks, and must consider patient-specific circumstances, values, preferences, 
and risk-aversion. Driven by the rarity of occult leiomyosarcoma and the reduced incidence 
of intra- and postoperative complications, LH with morcellation may be a more cost-
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effective and less invasive alternative to AH and ought to remain an option for women 
needing hysterectomy for large fibroids.
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Figure 1. Decision Tree
Women requiring hysterectomy for an enlarged uterus could undergo laparoscopic or 
abdominal hysterectomy. In either approach, death could occur immediately after the 
procedure. Women who survive the procedure could experience immediate surgical 
complications (blood transfusion, wound infection, or vaginal cuff dehiscence) and/or longer 
term surgical complications (hernia and venous thromboembolism). Women who had occult 
leiomyosarcoma at the time of the procedure would undergo treatment, after which point 
they could recover or die (sarcoma-related death). (Reproduced with permission from 
reference 13)
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Figure 2. Laparoscopic vs. abdominal hysterectomy incremental cost-effectiveness plane
In the ICER plane, the horizontal axis represents the difference in QALY gained between 
LH and AH. The vertical axis represents the difference in cost. These differences are 
therefore the incremental effectiveness (QALY gained) and incremental costs (dollars) when 
comparing LH to AH. Each triangle represents an ICER corresponding to the outcome 
observed in the probabilistic sensitivity analysis. The dark solid line from the origin 
extending into the upper right quadrant represents the willingness-to-pay threshold of 
$50,000/QALY gained – any point falling above this line would exceed that threshold. 
Approximately 17% of all estimated ICER points fall above this line. Points that fall to the 
right of 0 on the x-axis and below 0 on the y-axis represent scenarios in which LH is both 
more effective and less costly than AH. This represents a dominant scenario. Approximately 
68% of all estimated ICER points are cost savings where LH is dominant.
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81
87
,6
51
$3
2,6
48
do
m
in
at
es
U
til
ity
 a
ss
oc
ia
te
d 
w
ith
 h
ys
te
re
ct
om
y 
fo
r f
ib
ro
id
s (
AH
)
0.
72
do
m
in
at
es
1.
0
do
m
in
at
es
A
H
, a
bd
om
in
al
 h
ys
te
re
ct
om
y;
 IC
ER
, i
nc
re
m
en
ta
l c
os
t-e
ffe
ct
iv
en
es
s r
at
io
; L
H
, l
ap
ar
os
co
pi
c 
hy
ste
re
ct
om
y;
 Q
AL
Y,
 qu
ali
ty-
ad
jus
ted
 lif
e-y
ear
 D
om
ina
tes
 in
dic
ate
s a
 ne
ga
tiv
e I
CE
R,
 in
 w
hic
h L
H 
is 
bo
th 
les
s 
ex
pe
ns
iv
e 
an
d 
m
or
e 
ef
fe
ct
iv
e 
co
m
pa
re
d 
to
 A
H
N
ot
es
: T
hi
s t
ab
le
 d
ep
ic
ts 
on
e-
w
ay
 se
ns
iti
vi
ty
 a
na
ly
se
s i
n 
w
hi
ch
 e
ac
h 
pa
ra
m
et
er
 (l
eft
 co
lum
n) 
wa
s v
ari
ed
 w
as 
va
rie
d i
n t
urn
 ac
co
rdi
ng
 to
 pr
e-s
pe
cif
ied
 ra
ng
es,
 ho
ldi
ng
 al
l e
lse
 co
ns
tan
t. T
he
 ta
ble
 pr
ese
nts
 th
e 
se
n
sit
iv
ity
 a
na
ly
sis
 o
ut
co
m
es
, i
n 
ra
nk
-o
rd
er
, o
f t
he
 p
ar
am
et
er
s t
ha
t h
ad
 th
e 
m
os
t s
ig
ni
fic
an
t e
ffe
ct
 o
n 
ou
r o
ut
co
m
e 
(IC
ER
). F
or 
ex
am
ple
, th
e e
sti
ma
ted
 op
era
tiv
e c
os
ts 
of 
LH
 w
ere
 th
e b
igg
est
 dr
ive
r: 
wh
en
 
th
is 
in
pu
t p
ar
am
et
er
 w
as
 se
t t
o 
th
e 
lo
w
-e
nd
 o
f t
he
 e
sti
m
at
ed
 ra
ng
e 
($7
,26
8),
 L
H 
do
mi
na
tes
 A
H 
– i
t is
 bo
th 
les
s e
xp
en
siv
e a
nd
 yi
eld
s m
ore
 Q
AL
Ys
. H
ow
ev
er,
 w
he
n t
he
 co
st 
of 
LH
 is
 in
ste
ad
 se
t to
 th
e h
igh
-
en
d 
of
 th
e 
es
tim
at
ed
 ra
ng
e 
($3
5,5
84
), t
he
 $/
QA
LY
 co
mp
ari
ng
 L
H 
to 
AH
 is
 $1
20
,25
9/Q
AL
Y.
 “O
pe
rat
ive
 co
sts
” w
ere
 de
riv
ed
 fr
om
 m
icr
o-c
os
tin
g a
pp
roa
ch
es 
an
d i
nc
lud
ed
 op
era
tiv
e e
xp
en
ses
, s
up
pli
es,
 
eq
ui
pm
en
t a
nd
 in
str
um
en
ts,
 a
nd
 p
hy
sic
ia
n 
an
d 
sta
ff 
co
sts
. T
he
 p
ro
ce
ss
 o
f v
ar
yi
ng
 in
pu
ts 
be
tw
ee
n 
th
ei
r l
ow
 a
nd
 h
ig
h 
ra
ng
e,
 h
ol
di
ng
 a
ll 
el
se
 c
on
sta
nt
, w
as
 th
en
 re
pe
at
ed
 fo
r a
ll 
pa
ra
m
et
er
s; 
th
e 
th
re
e 
m
os
t 
in
flu
en
tia
l a
re
 p
re
se
nt
ed
 h
er
e.
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